JP2005506292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506292A5 JP2005506292A5 JP2002571458A JP2002571458A JP2005506292A5 JP 2005506292 A5 JP2005506292 A5 JP 2005506292A5 JP 2002571458 A JP2002571458 A JP 2002571458A JP 2002571458 A JP2002571458 A JP 2002571458A JP 2005506292 A5 JP2005506292 A5 JP 2005506292A5
- Authority
- JP
- Japan
- Prior art keywords
- lower alkyl
- group
- independently
- alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 394
- 229910052731 fluorine Inorganic materials 0.000 claims description 207
- 229910052739 hydrogen Inorganic materials 0.000 claims description 203
- 229910052801 chlorine Inorganic materials 0.000 claims description 152
- 229910052740 iodine Inorganic materials 0.000 claims description 149
- 150000001875 compounds Chemical class 0.000 claims description 147
- -1 2,6-difluorophenyl Chemical group 0.000 claims description 144
- 229910052794 bromium Inorganic materials 0.000 claims description 144
- 125000003118 aryl group Chemical group 0.000 claims description 124
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 73
- 229910052760 oxygen Inorganic materials 0.000 claims description 68
- 229910052717 sulfur Inorganic materials 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 39
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 38
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 28
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 28
- 210000005013 brain tissue Anatomy 0.000 claims description 26
- 239000000047 product Substances 0.000 claims description 25
- 230000002829 reductive effect Effects 0.000 claims description 16
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 230000001575 pathological effect Effects 0.000 claims description 14
- MQPUAVYKVIHUJP-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C(Cl)=C1 MQPUAVYKVIHUJP-UHFFFAOYSA-N 0.000 claims description 13
- 229910052786 argon Inorganic materials 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 6
- 230000000903 blocking effect Effects 0.000 claims description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- AIHIHVZYAAMDPM-QMMMGPOBSA-N [(2s)-oxiran-2-yl]methyl 3-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)OC[C@H]2OC2)=C1 AIHIHVZYAAMDPM-QMMMGPOBSA-N 0.000 claims description 5
- BMURNNVCEDFRDD-AWEZNQCLSA-N n-[2-[(2s)-3-[2-(3,4-dichlorophenyl)ethylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1OC[C@@H](O)CNCCC1=CC=C(Cl)C(Cl)=C1 BMURNNVCEDFRDD-AWEZNQCLSA-N 0.000 claims description 5
- JWEPJKHYSIKQNJ-CQSZACIVSA-N (2r)-1-[2-(3,4-dichlorophenyl)ethylamino]-3-(4-nitrophenoxy)propan-2-ol Chemical compound C([C@@H](O)COC=1C=CC(=CC=1)[N+]([O-])=O)NCCC1=CC=C(Cl)C(Cl)=C1 JWEPJKHYSIKQNJ-CQSZACIVSA-N 0.000 claims description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- WWGZWGCAWTUHCL-UHFFFAOYSA-N N-[4-[3-[2-(3,4-dichlorophenyl)ethyl-[(3-fluorophenyl)methyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OCC(O)CN(CC=1C=C(F)C=CC=1)CCC1=CC=C(Cl)C(Cl)=C1 WWGZWGCAWTUHCL-UHFFFAOYSA-N 0.000 claims description 4
- 230000007954 hypoxia Effects 0.000 claims description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 4
- 210000000278 spinal cord Anatomy 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- FTJXZACAQRDRNT-UHFFFAOYSA-N (4-fluorophenyl)-[1-(4-phenylbutyl)-4-piperidinyl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCCCC=2C=CC=CC=2)CC1 FTJXZACAQRDRNT-UHFFFAOYSA-N 0.000 claims description 3
- BATPBOZTBNNDLN-UHFFFAOYSA-N (8-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-dipropylazanium;bromide Chemical compound Br.C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 BATPBOZTBNNDLN-UHFFFAOYSA-N 0.000 claims description 3
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 3
- RFNFFVDVGWOSNZ-UHFFFAOYSA-N 2-(1-benzofuran-2-yl)-4,5-dihydro-1h-imidazole;hydrochloride Chemical compound Cl.N1CCN=C1C1=CC2=CC=CC=C2O1 RFNFFVDVGWOSNZ-UHFFFAOYSA-N 0.000 claims description 3
- HFVRPDJQMMPXJJ-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-methylethanamine Chemical compound CNCCC1=CC=C(Cl)C(Cl)=C1 HFVRPDJQMMPXJJ-UHFFFAOYSA-N 0.000 claims description 3
- KCLWVAYPAFNJFB-UHFFFAOYSA-N 2-(4-chloroanilino)-4-(4-phenylpiperazin-1-yl)cyclopent-2-en-1-one Chemical compound C1=CC(Cl)=CC=C1NC1=CC(N2CCN(CC2)C=2C=CC=CC=2)CC1=O KCLWVAYPAFNJFB-UHFFFAOYSA-N 0.000 claims description 3
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 claims description 3
- OGJGQVFWEPNYSB-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-1H-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C3=CC=CN=C3NC=2)CC1 OGJGQVFWEPNYSB-UHFFFAOYSA-N 0.000 claims description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 3
- ARVWXTTUXSMAMS-UHFFFAOYSA-N 5-[(4-aminophenoxy)methyl]-2-phenyl-n-(2-phenylethyl)-1,3-oxazolidin-3-amine Chemical compound C1=CC(N)=CC=C1OCC1OC(C=2C=CC=CC=2)N(NCCC=2C=CC=CC=2)C1 ARVWXTTUXSMAMS-UHFFFAOYSA-N 0.000 claims description 3
- SBOWBHMARAESGX-UHFFFAOYSA-N 5-[(4-nitrophenoxy)methyl]-2-phenyl-n-(2-phenylethyl)-1,3-oxazolidin-3-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCC1OC(C=2C=CC=CC=2)N(NCCC=2C=CC=CC=2)C1 SBOWBHMARAESGX-UHFFFAOYSA-N 0.000 claims description 3
- DEYFWGXTPWNADC-UHFFFAOYSA-N 6-[2-phenylethyl(propyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CC=C1 DEYFWGXTPWNADC-UHFFFAOYSA-N 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- CXYDYDCHYJXOEY-MRVPVSSYSA-N [(2r)-oxiran-2-yl]methyl 4-nitrobenzenesulfonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)OC[C@@H]1OC1 CXYDYDCHYJXOEY-MRVPVSSYSA-N 0.000 claims description 3
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 3
- IVVQFDKQRZADPE-UHFFFAOYSA-N [1-[acetyl-[2-(3,4-dichlorophenyl)ethyl]amino]-3-[4-(methanesulfonamido)phenoxy]propan-2-yl] acetate Chemical compound C=1C=C(Cl)C(Cl)=CC=1CCN(C(C)=O)CC(OC(=O)C)COC1=CC=C(NS(C)(=O)=O)C=C1 IVVQFDKQRZADPE-UHFFFAOYSA-N 0.000 claims description 3
- QAUVAHYHKLRJCQ-UHFFFAOYSA-N benoxathian Chemical compound COC1=CC=CC(OC)=C1OCCNCC1OC2=CC=CC=C2SC1 QAUVAHYHKLRJCQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 claims description 3
- 229940043279 diisopropylamine Drugs 0.000 claims description 3
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 3
- 229960003878 haloperidol Drugs 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 208000005809 status epilepticus Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- SMKKEOQDQNCTGL-SSDOTTSWSA-N (2r)-2-[(2-nitrophenoxy)methyl]oxirane Chemical compound [O-][N+](=O)C1=CC=CC=C1OC[C@@H]1OC1 SMKKEOQDQNCTGL-SSDOTTSWSA-N 0.000 claims description 2
- JWEPJKHYSIKQNJ-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenyl)ethylamino]-3-(4-nitrophenoxy)propan-2-ol Chemical compound C=1C=C([N+]([O-])=O)C=CC=1OCC(O)CNCCC1=CC=C(Cl)C(Cl)=C1 JWEPJKHYSIKQNJ-UHFFFAOYSA-N 0.000 claims description 2
- MWAGUKZCDDRDCS-UHFFFAOYSA-N 1-nitro-4-(4-nitrophenoxy)benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C([N+]([O-])=O)C=C1 MWAGUKZCDDRDCS-UHFFFAOYSA-N 0.000 claims description 2
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- CEZWHBSRAZAKQA-UHFFFAOYSA-N 3,4-dichloro-n-ethylpentan-1-amine Chemical compound CCNCCC(Cl)C(C)Cl CEZWHBSRAZAKQA-UHFFFAOYSA-N 0.000 claims description 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 2
- SVZCHDXRIPMIIX-UHFFFAOYSA-N C1=CC(NS(=O)(=O)C)=CC=C1OCC(O)CN(CC=1C(=C(F)C(F)=CC=1)F)CCC1=CC=C(Cl)C(Cl)=C1 Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OCC(O)CN(CC=1C(=C(F)C(F)=CC=1)F)CCC1=CC=C(Cl)C(Cl)=C1 SVZCHDXRIPMIIX-UHFFFAOYSA-N 0.000 claims description 2
- KQGYIJNPHWXNEA-UHFFFAOYSA-N C1=CC(NS(=O)(=O)C)=CC=C1OCC(O)CN(CC=1C(=CC=CC=1F)F)CCC1=CC=C(Cl)C(Cl)=C1 Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OCC(O)CN(CC=1C(=CC=CC=1F)F)CCC1=CC=C(Cl)C(Cl)=C1 KQGYIJNPHWXNEA-UHFFFAOYSA-N 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- REAHNDOSRQJMDW-UHFFFAOYSA-N N-[4-[3-[2-(3,4-dichlorophenyl)ethyl-[(2-fluorophenyl)methyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OCC(O)CN(CC=1C(=CC=CC=1)F)CCC1=CC=C(Cl)C(Cl)=C1 REAHNDOSRQJMDW-UHFFFAOYSA-N 0.000 claims description 2
- BQBSHJUQVIWEFM-UHFFFAOYSA-N N-[4-[3-[2-(3,4-dichlorophenyl)ethyl-methylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1OCC(O)CN(C)CCC1=CC=C(Cl)C(Cl)=C1 BQBSHJUQVIWEFM-UHFFFAOYSA-N 0.000 claims description 2
- BYXDWEZFFJZFFM-UHFFFAOYSA-N N-[4-[[3-(3,4-dichlorophenyl)-4-ethyl-4-methyl-2-oxo-1,3-oxazolidin-5-yl]oxy]phenyl]methanesulfonamide Chemical compound ClC=1C=C(C=CC=1Cl)N1C(OC(C1(C)CC)OC1=CC=C(C=C1)NS(=O)(=O)C)=O BYXDWEZFFJZFFM-UHFFFAOYSA-N 0.000 claims description 2
- 206010038669 Respiratory arrest Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- IIWOUNLDWKZMQI-UHFFFAOYSA-N n'-[(2-methoxyphenyl)methyl]-n-[2-[2-[6-[(2-methoxyphenyl)methylamino]hexylamino]ethyldisulfanyl]ethyl]hexane-1,6-diamine Chemical compound COC1=CC=CC=C1CNCCCCCCNCCSSCCNCCCCCCNCC1=CC=CC=C1OC IIWOUNLDWKZMQI-UHFFFAOYSA-N 0.000 claims description 2
- BMURNNVCEDFRDD-CQSZACIVSA-N n-[2-[(2r)-3-[2-(3,4-dichlorophenyl)ethylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1OC[C@H](O)CNCCC1=CC=C(Cl)C(Cl)=C1 BMURNNVCEDFRDD-CQSZACIVSA-N 0.000 claims description 2
- ZHSWCMJZNQYJJJ-MRVPVSSYSA-N n-[2-[[(2r)-oxiran-2-yl]methoxy]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1OC[C@@H]1OC1 ZHSWCMJZNQYJJJ-MRVPVSSYSA-N 0.000 claims description 2
- JBMYYJHKNSMSBI-UHFFFAOYSA-N n-[3-[3-[2-(3,4-dichlorophenyl)ethylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(OCC(O)CNCCC=2C=C(Cl)C(Cl)=CC=2)=C1 JBMYYJHKNSMSBI-UHFFFAOYSA-N 0.000 claims description 2
- CYNFCGYKMNBNLR-UHFFFAOYSA-N n-[4-[3-[2-(3,4-dichlorophenyl)ethyl-(2-hydroxyethyl)amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OCC(O)CN(CCO)CCC1=CC=C(Cl)C(Cl)=C1 CYNFCGYKMNBNLR-UHFFFAOYSA-N 0.000 claims description 2
- DUYHOUPHQKVIPQ-UHFFFAOYSA-N n-[4-[3-[2-(3,4-dichlorophenyl)ethyl-[(2,3,4,5,6-pentafluorophenyl)methyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OCC(O)CN(CC=1C(=C(F)C(F)=C(F)C=1F)F)CCC1=CC=C(Cl)C(Cl)=C1 DUYHOUPHQKVIPQ-UHFFFAOYSA-N 0.000 claims description 2
- CGABCYQENPATFM-UHFFFAOYSA-N n-[4-[3-[2-(3,4-dichlorophenyl)ethylamino]-2-hydroxypropoxy]phenyl]benzenesulfonamide Chemical compound C=1C=C(NS(=O)(=O)C=2C=CC=CC=2)C=CC=1OCC(O)CNCCC1=CC=C(Cl)C(Cl)=C1 CGABCYQENPATFM-UHFFFAOYSA-N 0.000 claims description 2
- GEFDXUZHLNJUMR-UHFFFAOYSA-N n-[4-[3-[2-(3,4-dichlorophenyl)ethylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OCC(O)CNCCC1=CC=C(Cl)C(Cl)=C1 GEFDXUZHLNJUMR-UHFFFAOYSA-N 0.000 claims description 2
- XFGNLELAXLYWEJ-UHFFFAOYSA-N n-[4-[4-(methanesulfonamido)phenoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC1=CC=C(NS(C)(=O)=O)C=C1 XFGNLELAXLYWEJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- ODNDMTWHRYECKX-UHFFFAOYSA-N 7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol;hydrobromide Chemical compound Br.C1=C(O)C=C2CC(N(CCC)CCC)CCC2=C1 ODNDMTWHRYECKX-UHFFFAOYSA-N 0.000 claims 2
- 239000007795 chemical reaction product Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- DSYNOKVSDSJMLB-UHFFFAOYSA-N 7-[2-(1h-imidazol-5-yl)ethylamino]-n-[4-(trifluoromethyl)phenyl]octanamide Chemical compound C=1NC=NC=1CCNC(C)CCCCCC(=O)NC1=CC=C(C(F)(F)F)C=C1 DSYNOKVSDSJMLB-UHFFFAOYSA-N 0.000 claims 1
- XQPLBOPPSBAOCM-UHFFFAOYSA-N N-[4-[3-[benzyl-[2-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OCC(O)CN(CC=1C=CC=CC=1)CCC1=CC=C(Cl)C(Cl)=C1 XQPLBOPPSBAOCM-UHFFFAOYSA-N 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- KHLCOSGYTJPDNE-UHFFFAOYSA-N n-[4-[3-[2-(3,4-dichlorophenyl)ethyl-ethylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1OCC(O)CN(CC)CCC1=CC=C(Cl)C(Cl)=C1 KHLCOSGYTJPDNE-UHFFFAOYSA-N 0.000 claims 1
- GTHAOZQJYKITBT-UHFFFAOYSA-N n-[4-[3-[2-(3,4-dichlorophenyl)ethyl-propylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1OCC(O)CN(CCC)CCC1=CC=C(Cl)C(Cl)=C1 GTHAOZQJYKITBT-UHFFFAOYSA-N 0.000 claims 1
- NHYMWKHINJIWJL-UHFFFAOYSA-N n-[4-[3-[butyl-[2-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1OCC(O)CN(CCCC)CCC1=CC=C(Cl)C(Cl)=C1 NHYMWKHINJIWJL-UHFFFAOYSA-N 0.000 claims 1
- LTHCSWBWNVGEFE-UHFFFAOYSA-N octanamide Chemical compound CCCCCCCC(N)=O LTHCSWBWNVGEFE-UHFFFAOYSA-N 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 125000006510 trifluorobenzyl group Chemical group 0.000 claims 1
- 229960002341 trifluperidol Drugs 0.000 claims 1
- GPMXUUPHFNMNDH-UHFFFAOYSA-N trifluperidol Chemical compound C1CC(O)(C=2C=C(C=CC=2)C(F)(F)F)CCN1CCCC(=O)C1=CC=C(F)C=C1 GPMXUUPHFNMNDH-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 84
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 238000005160 1H NMR spectroscopy Methods 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000002360 preparation method Methods 0.000 description 30
- 239000007787 solid Substances 0.000 description 30
- 239000002904 solvent Substances 0.000 description 30
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 24
- 238000003818 flash chromatography Methods 0.000 description 22
- 239000007789 gas Substances 0.000 description 19
- 150000003840 hydrochlorides Chemical class 0.000 description 19
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 14
- 229930195712 glutamate Natural products 0.000 description 14
- 210000000287 oocyte Anatomy 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 9
- 108010038912 Retinoid X Receptors Proteins 0.000 description 9
- 208000006011 Stroke Diseases 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 8
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 0 CC1=*I***1 Chemical compound CC1=*I***1 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 241000269370 Xenopus <genus> Species 0.000 description 6
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical compound NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 6
- 238000007142 ring opening reaction Methods 0.000 description 6
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 6
- 206010019196 Head injury Diseases 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- SMKKEOQDQNCTGL-ZETCQYMHSA-N (2s)-2-[(2-nitrophenoxy)methyl]oxirane Chemical compound [O-][N+](=O)C1=CC=CC=C1OC[C@H]1OC1 SMKKEOQDQNCTGL-ZETCQYMHSA-N 0.000 description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 4
- ALBWDNPLQOJPCK-SECBINFHSA-N 4-[[(2s)-oxiran-2-yl]methoxy]aniline Chemical compound C1=CC(N)=CC=C1OC[C@H]1OC1 ALBWDNPLQOJPCK-SECBINFHSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000005841 biaryl group Chemical group 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 150000002118 epoxides Chemical group 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000002964 excitative effect Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 229960003998 ifenprodil Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- SVZCHDXRIPMIIX-IBGZPJMESA-N n-[4-[(2s)-3-[2-(3,4-dichlorophenyl)ethyl-[(2,3,4-trifluorophenyl)methyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC[C@@H](O)CN(CC=1C(=C(F)C(F)=CC=1)F)CCC1=CC=C(Cl)C(Cl)=C1 SVZCHDXRIPMIIX-IBGZPJMESA-N 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 3
- JWEPJKHYSIKQNJ-AWEZNQCLSA-N (2s)-1-[2-(3,4-dichlorophenyl)ethylamino]-3-(4-nitrophenoxy)propan-2-ol Chemical compound C([C@H](O)COC=1C=CC(=CC=1)[N+]([O-])=O)NCCC1=CC=C(Cl)C(Cl)=C1 JWEPJKHYSIKQNJ-AWEZNQCLSA-N 0.000 description 2
- CNJLXLVVZBTEOC-SECBINFHSA-N (2s)-2-[(3-nitrophenoxy)methyl]oxirane Chemical compound [O-][N+](=O)C1=CC=CC(OC[C@H]2OC2)=C1 CNJLXLVVZBTEOC-SECBINFHSA-N 0.000 description 2
- FPIGOBKNDYAZTP-SECBINFHSA-N (2s)-2-[(4-nitrophenoxy)methyl]oxirane Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC[C@H]1OC1 FPIGOBKNDYAZTP-SECBINFHSA-N 0.000 description 2
- CLASKYWJDPEUGM-FQEVSTJZSA-N 2-[2-(3,4-dichlorophenyl)ethyl-[(2s)-2-hydroxy-3-[4-(methanesulfonamido)phenoxy]propyl]amino]ethyl butanoate Chemical compound C([C@H](O)COC=1C=CC(NS(C)(=O)=O)=CC=1)N(CCOC(=O)CCC)CCC1=CC=C(Cl)C(Cl)=C1 CLASKYWJDPEUGM-FQEVSTJZSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229950006768 phenylethanolamine Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- POJGYDWODMYCHP-ZDUSSCGKSA-N (2s)-1-[2-(3,4-dichlorophenyl)ethylamino]-3-(2-nitrophenoxy)propan-2-ol Chemical compound C([C@H](O)COC=1C(=CC=CC=1)[N+]([O-])=O)NCCC1=CC=C(Cl)C(Cl)=C1 POJGYDWODMYCHP-ZDUSSCGKSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- BZIKFXDSIMRAIL-SECBINFHSA-N 3-[[(2s)-oxiran-2-yl]methoxy]aniline Chemical compound NC1=CC=CC(OC[C@H]2OC2)=C1 BZIKFXDSIMRAIL-SECBINFHSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- RTZZCYNQPHTPPL-UHFFFAOYSA-N 3-nitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1 RTZZCYNQPHTPPL-UHFFFAOYSA-N 0.000 description 1
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- BLYMJBIZMIGWFK-UHFFFAOYSA-N 7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1=C(O)C=C2CC(N(CCC)CCC)CCC2=C1 BLYMJBIZMIGWFK-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 229940122459 Glutamate antagonist Drugs 0.000 description 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 1
- 102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 1
- 102100038942 Glutamate receptor ionotropic, NMDA 3A Human genes 0.000 description 1
- 102100038958 Glutamate receptor ionotropic, NMDA 3B Human genes 0.000 description 1
- 101710195174 Glutamate receptor ionotropic, NMDA 3B Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- KUBONGDXTUOOLM-UHFFFAOYSA-N N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1NCCCOC(C=1)=CC=CC=1CN1CCCCC1 KUBONGDXTUOOLM-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 description 1
- 108091008644 NR2D Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000008850 allosteric inhibition Effects 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000002431 glycine receptor agonist Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- JBMYYJHKNSMSBI-HNNXBMFYSA-N n-[3-[(2s)-3-[2-(3,4-dichlorophenyl)ethylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(OC[C@@H](O)CNCCC=2C=C(Cl)C(Cl)=CC=2)=C1 JBMYYJHKNSMSBI-HNNXBMFYSA-N 0.000 description 1
- DMZXRGOAFRGYAI-SNVBAGLBSA-N n-[3-[[(2s)-oxiran-2-yl]methoxy]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(OC[C@H]2OC2)=C1 DMZXRGOAFRGYAI-SNVBAGLBSA-N 0.000 description 1
- CYNFCGYKMNBNLR-KRWDZBQOSA-N n-[4-[(2s)-3-[2-(3,4-dichlorophenyl)ethyl-(2-hydroxyethyl)amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC[C@@H](O)CN(CCO)CCC1=CC=C(Cl)C(Cl)=C1 CYNFCGYKMNBNLR-KRWDZBQOSA-N 0.000 description 1
- DUYHOUPHQKVIPQ-INIZCTEOSA-N n-[4-[(2s)-3-[2-(3,4-dichlorophenyl)ethyl-[(2,3,4,5,6-pentafluorophenyl)methyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC[C@@H](O)CN(CC=1C(=C(F)C(F)=C(F)C=1F)F)CCC1=CC=C(Cl)C(Cl)=C1 DUYHOUPHQKVIPQ-INIZCTEOSA-N 0.000 description 1
- KQGYIJNPHWXNEA-IBGZPJMESA-N n-[4-[(2s)-3-[2-(3,4-dichlorophenyl)ethyl-[(2,6-difluorophenyl)methyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC[C@@H](O)CN(CC=1C(=CC=CC=1F)F)CCC1=CC=C(Cl)C(Cl)=C1 KQGYIJNPHWXNEA-IBGZPJMESA-N 0.000 description 1
- REAHNDOSRQJMDW-NRFANRHFSA-N n-[4-[(2s)-3-[2-(3,4-dichlorophenyl)ethyl-[(2-fluorophenyl)methyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC[C@@H](O)CN(CC=1C(=CC=CC=1)F)CCC1=CC=C(Cl)C(Cl)=C1 REAHNDOSRQJMDW-NRFANRHFSA-N 0.000 description 1
- WWGZWGCAWTUHCL-QFIPXVFZSA-N n-[4-[(2s)-3-[2-(3,4-dichlorophenyl)ethyl-[(3-fluorophenyl)methyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC[C@@H](O)CN(CC=1C=C(F)C=CC=1)CCC1=CC=C(Cl)C(Cl)=C1 WWGZWGCAWTUHCL-QFIPXVFZSA-N 0.000 description 1
- PWOOSNJNGOSCCW-QFIPXVFZSA-N n-[4-[(2s)-3-[2-(3,4-dichlorophenyl)ethyl-[(4-fluorophenyl)methyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC[C@@H](O)CN(CC=1C=CC(F)=CC=1)CCC1=CC=C(Cl)C(Cl)=C1 PWOOSNJNGOSCCW-QFIPXVFZSA-N 0.000 description 1
- KHLCOSGYTJPDNE-KRWDZBQOSA-N n-[4-[(2s)-3-[2-(3,4-dichlorophenyl)ethyl-ethylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C([C@H](O)COC=1C=CC(NS(C)(=O)=O)=CC=1)N(CC)CCC1=CC=C(Cl)C(Cl)=C1 KHLCOSGYTJPDNE-KRWDZBQOSA-N 0.000 description 1
- BQBSHJUQVIWEFM-INIZCTEOSA-N n-[4-[(2s)-3-[2-(3,4-dichlorophenyl)ethyl-methylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C([C@H](O)COC=1C=CC(NS(C)(=O)=O)=CC=1)N(C)CCC1=CC=C(Cl)C(Cl)=C1 BQBSHJUQVIWEFM-INIZCTEOSA-N 0.000 description 1
- GTHAOZQJYKITBT-SFHVURJKSA-N n-[4-[(2s)-3-[2-(3,4-dichlorophenyl)ethyl-propylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C([C@H](O)COC=1C=CC(NS(C)(=O)=O)=CC=1)N(CCC)CCC1=CC=C(Cl)C(Cl)=C1 GTHAOZQJYKITBT-SFHVURJKSA-N 0.000 description 1
- GEFDXUZHLNJUMR-HNNXBMFYSA-N n-[4-[(2s)-3-[2-(3,4-dichlorophenyl)ethylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC[C@@H](O)CNCCC1=CC=C(Cl)C(Cl)=C1 GEFDXUZHLNJUMR-HNNXBMFYSA-N 0.000 description 1
- XQPLBOPPSBAOCM-QFIPXVFZSA-N n-[4-[(2s)-3-[benzyl-[2-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC[C@@H](O)CN(CC=1C=CC=CC=1)CCC1=CC=C(Cl)C(Cl)=C1 XQPLBOPPSBAOCM-QFIPXVFZSA-N 0.000 description 1
- NHYMWKHINJIWJL-IBGZPJMESA-N n-[4-[(2s)-3-[butyl-[2-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropoxy]phenyl]methanesulfonamide Chemical compound C([C@H](O)COC=1C=CC(NS(C)(=O)=O)=CC=1)N(CCCC)CCC1=CC=C(Cl)C(Cl)=C1 NHYMWKHINJIWJL-IBGZPJMESA-N 0.000 description 1
- RNNIOBHRSCQMJY-CQSZACIVSA-N n-[4-[[(2s)-oxiran-2-yl]methoxy]phenyl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1)=CC=C1OC[C@@H]1CO1 RNNIOBHRSCQMJY-CQSZACIVSA-N 0.000 description 1
- DMBDRKKEZLXIBV-SNVBAGLBSA-N n-[4-[[(2s)-oxiran-2-yl]methoxy]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1OC[C@H]1OC1 DMBDRKKEZLXIBV-SNVBAGLBSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- DVZHATPPZVLWKB-LLVKDONJSA-N n-methyl-n-[4-[[(2s)-oxiran-2-yl]methoxy]phenyl]methanesulfonamide Chemical compound C1=CC(N(C)S(C)(=O)=O)=CC=C1OC[C@H]1OC1 DVZHATPPZVLWKB-LLVKDONJSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 108091008589 nuclear estrogen receptors Proteins 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- FCJSHPDYVMKCHI-UHFFFAOYSA-N phenyl benzoate Chemical group C=1C=CC=CC=1C(=O)OC1=CC=CC=C1 FCJSHPDYVMKCHI-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108091008646 testicular receptors Proteins 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27420501P | 2001-03-08 | 2001-03-08 | |
| PCT/US2002/007033 WO2002072542A2 (en) | 2001-03-08 | 2002-03-08 | Ph-dependent nmda receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506292A JP2005506292A (ja) | 2005-03-03 |
| JP2005506292A5 true JP2005506292A5 (cg-RX-API-DMAC7.html) | 2007-12-20 |
Family
ID=23047230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002571458A Pending JP2005506292A (ja) | 2001-03-08 | 2002-03-08 | ｐＨに依存するＮＭＤＡレセプターアンタゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7375136B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1436258A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005506292A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002250256B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2440284A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002072542A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7375136B2 (en) * | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
| ES2686625T3 (es) * | 2001-12-06 | 2018-10-18 | Fibrogen, Inc. | Métodos para el tratamiento o prevención de la anemia |
| JP2004123562A (ja) * | 2002-09-30 | 2004-04-22 | Japan Science & Technology Corp | 神経細胞死抑制作用を有する化合物を用いた医薬 |
| US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| WO2005089430A2 (en) * | 2004-03-17 | 2005-09-29 | Neurorecovery, Inc. | System and method for neurological injury detection, classification and subsequent injury amelioration |
| EP1791569A4 (en) * | 2004-08-23 | 2009-12-16 | Univ Emory | Improved selection of-ph dependent compounds for in vivo therapy |
| EP1976495A2 (en) * | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| DK2091948T3 (da) | 2006-11-30 | 2012-07-23 | Probiodrug Ag | Nye inhibitorer af glutaminylcyclase |
| EP2481408A3 (en) | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| US8609649B2 (en) | 2007-03-20 | 2013-12-17 | Brandeis University | Compositions and methods for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related neurological diseases |
| WO2008120655A1 (ja) | 2007-03-30 | 2008-10-09 | Institute Of Medicinal Molecular Design, Inc. | Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するオキサゾリジノン誘導体 |
| DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
| CN103058957A (zh) * | 2007-06-29 | 2013-04-24 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
| BRPI0820406A2 (pt) * | 2007-11-06 | 2015-05-19 | Univ Emory | Métodos para identificar aumento de antagonistas do receptor nmda |
| KR20110016891A (ko) * | 2008-05-09 | 2011-02-18 | 에모리 유니버시티 | 신경정신 장애의 치료를 위한 ｎｍｄａ 수용체 길항물질 |
| US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
| WO2011101774A1 (en) | 2010-02-16 | 2011-08-25 | Pfizer Inc. | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| ES2481823T3 (es) | 2010-03-10 | 2014-07-31 | Probiodrug Ag | Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| CN104490872A (zh) * | 2014-12-11 | 2015-04-08 | 温州医科大学附属第一医院 | 2-(2-苯并呋喃基)-2-咪唑啉治疗神经系统线粒体损伤疾病中的用途 |
| EP3383429B1 (en) | 2015-11-30 | 2020-10-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Nmdar antagonists for the treatment of tumor angiogenesis |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| WO2021019375A1 (en) * | 2019-07-31 | 2021-02-04 | Sea4Us - Biotecnologia E Recursos Marinhos, Lda. | Kv1.3 antagonists for use in the treatment of chronic and acute pain |
| CA3149175A1 (en) | 2019-07-31 | 2021-02-04 | Sea4Us - Biotecnologia E Recursos Marinhos, Lda. | Nitenin analogue compounds and their use in the treatment of chronic and acute pain |
| AU2022339672B2 (en) | 2021-09-02 | 2025-10-16 | Emory University | Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US509009A (en) * | 1893-11-21 | Hermann wecker | ||
| EG18188A (en) * | 1986-05-01 | 1992-09-30 | Pfizer Ltd | Process for preparation anti-arhythmia agents |
| US4906779A (en) | 1986-07-10 | 1990-03-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
| US5093525A (en) | 1986-07-10 | 1992-03-03 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
| US5190976A (en) | 1986-07-10 | 1993-03-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
| US5179085A (en) | 1989-03-15 | 1993-01-12 | Warner-Lambert Company | N-substituted α-amino acids and derivatives thereof having pharmaceutical activity |
| US4957909A (en) | 1989-05-04 | 1990-09-18 | American Home Products Corporation | Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents |
| US4924008A (en) | 1989-05-04 | 1990-05-08 | American Home Products Corporation | Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents |
| US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| US5500419A (en) | 1989-09-19 | 1996-03-19 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5326756A (en) | 1989-09-19 | 1994-07-05 | Merrell Dow Pharmaceuticals Inc. | R-4-oxo-5 phosphononorvaline used as NMDA antagonists |
| US5095009A (en) | 1990-04-11 | 1992-03-10 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5474990A (en) | 1989-10-20 | 1995-12-12 | Olney; John W. | Barbiturates as safening agents in conjunction with NMDA antagonists |
| US5767130A (en) | 1989-10-20 | 1998-06-16 | Olney; John W. | Use of kainic acid antagonists to prevent toxic side effects of NMDA antagonists |
| US5629307A (en) | 1989-10-20 | 1997-05-13 | Olney; John W. | Use of ibogaine in reducing excitotoxic brain damage |
| EP0424179A3 (en) | 1989-10-20 | 1991-12-27 | John William Olney | Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration |
| US5034400A (en) | 1989-10-20 | 1991-07-23 | Olney John W | Method for preventing neurotoxic side effects of NMDA antagonists |
| US5132313A (en) | 1989-10-26 | 1992-07-21 | University Of Pittsburgh | Non-competitive NMDA receptor antagonists and methods for their use |
| US5013540A (en) | 1989-11-30 | 1991-05-07 | Board Of Regents, The University Of Texas System | Using NMDA receptor antagonists to reduce damage due to laser treatment |
| US5039528A (en) | 1989-12-11 | 1991-08-13 | Olney John W | EAA antagonists as anti-emetic drugs |
| US5336689A (en) | 1990-03-02 | 1994-08-09 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
| IE910719A1 (en) | 1990-03-02 | 1991-09-11 | Oregon State | Tri- and tetra-substituted guanidines and their use as¹excitatory amino acid and antagonists |
| US5262568A (en) | 1990-03-02 | 1993-11-16 | State Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
| GB9005318D0 (en) * | 1990-03-09 | 1990-05-02 | Isis Innovation | Antiarrhythmic agents |
| US5194430A (en) | 1990-05-17 | 1993-03-16 | Merrell Dow Pharmaceuticals Inc. | Heterocyclic-nmda antagonists |
| DE69118539T2 (de) | 1990-07-16 | 1996-09-19 | Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio | Exzitatorische Aminosäureantagonisten |
| ATE154010T1 (de) | 1990-10-15 | 1997-06-15 | Astra Ab | 2-phenyl- und 2-thienyl-(2)-piperidinderivate mit neuroprotektiven eigenschaften |
| US5189054A (en) | 1990-11-02 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | 3-amidoindolyl derivatives and pharmaceutical compositions thereof |
| US5118675A (en) | 1991-02-15 | 1992-06-02 | American Home Products Corporation | Quinoxaline phosphono-amino acids |
| US5606063A (en) | 1991-02-27 | 1997-02-25 | Merrell Pharmaceuticals Inc. | NMDA antagonists |
| WO1992015931A2 (fr) * | 1991-02-28 | 1992-09-17 | Thomson-Lcd | Registres a decalage redondants pour dispositifs de balayage |
| US5594007A (en) | 1991-04-18 | 1997-01-14 | Pfizer Inc. | Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols |
| DE4123106A1 (de) | 1991-07-09 | 1993-01-14 | Schering Ag | Arzneimittel zur behandlung von entzugssymptomen |
| US5124319A (en) | 1991-10-11 | 1992-06-23 | American Home Products Corporation | Benzimidazole phosphono-amino acids |
| US5710168A (en) | 1991-10-23 | 1998-01-20 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as neuroprotective agents |
| US5318985A (en) | 1991-12-20 | 1994-06-07 | Merrell Dow Pharmaceuticals Inc. | Potentiation of NMDA antagonists |
| US5441963A (en) | 1991-12-20 | 1995-08-15 | Merrell Dow Pharmaceuticals | Potentiation of NMDA antagonists |
| DE4222826A1 (de) | 1992-07-09 | 1994-01-13 | Schering Ag | Arzneimittel zur Verhinderung der Toleranzentwicklung während der Behandlung mit Benzodiazepin-Rezeptor-Bindenen Wirkstoffen |
| US5192751A (en) | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
| US5498610A (en) | 1992-11-06 | 1996-03-12 | Pfizer Inc. | Neuroprotective indolone and related derivatives |
| CA2111138A1 (en) | 1993-01-15 | 1994-07-16 | Thierry Godel | Octahydrophenanthrene derivatives |
| US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| US5834479A (en) | 1993-03-05 | 1998-11-10 | Mayer; David J. | Method and composition for alleviating pain |
| CA2115792C (en) | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
| US5519048A (en) | 1993-05-27 | 1996-05-21 | Merrell Pharmaceuticals Inc. | 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof |
| FR2707643B1 (fr) | 1993-07-16 | 1995-08-11 | Rhone Poulenc Rorer Sa | Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant. |
| US5395822A (en) | 1993-09-20 | 1995-03-07 | Izumi; Yukitoshi | Use of pyruvate to prevent neuronal degeneration associated with ischemia |
| IS4233A (is) | 1993-12-22 | 1995-06-23 | Astra Aktiebolag | Misleit hringtengd efnasambönd |
| US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| FR2717805B1 (fr) | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant . |
| EP0685466A1 (de) | 1994-06-02 | 1995-12-06 | Ciba-Geigy Ag | 3-Heteroaliphatyl- und 3-Hetero-(aryl)aliphatyl-2(1H)-chinolonderivate |
| DE69531691T2 (de) * | 1994-08-04 | 2004-07-08 | C & C Research Labs | Neues amin-derivat, verfahren zur herstellung und dessen verwendung als anti-arrhythmisches mittel |
| GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
| PL181532B1 (pl) | 1994-09-27 | 2001-08-31 | Yamanouchi Pharma Co Ltd | Pochodne 1,2,3,4-tetrahydrochinoksalinodionu PL PL PL PL PL PL PL PL PL |
| US5563157B1 (en) | 1994-10-31 | 1999-02-02 | Hoecst Marion Roussel Inc | Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof |
| FR2726275B1 (fr) | 1994-11-02 | 1996-12-06 | Rhone Poulenc Rorer Sa | Spiro heterocycle-imidazo(1,2-a)indeno(1,2-e)pyrazine)-4'- ones, leur preparation et les medicaments les contenants |
| US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
| PT828513E (pt) | 1995-05-26 | 2004-05-31 | Pfizer | Combinacoes contendo antagonistas selectivos de nmda para o tratamento do parkinsonismo |
| WO1997003677A1 (en) | 1995-07-24 | 1997-02-06 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| US5840731A (en) | 1995-08-02 | 1998-11-24 | Virginia Commonwealth University | Pain-alleviating drug composition and method for alleviating pain |
| MY132385A (en) | 1995-08-31 | 2007-10-31 | Novartis Ag | 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| TW427978B (en) | 1996-02-03 | 2001-04-01 | Hoffmann La Roche | Tetrahydroisoquinoline derivatives |
| WO1997032581A1 (en) * | 1996-03-08 | 1997-09-12 | F. Hoffmann-La Roche Ag | Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers |
| US6025369A (en) | 1996-05-03 | 2000-02-15 | The Board Of Regents Of The University Nebraska | N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis |
| TW498067B (en) | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
| ES2241055T3 (es) | 1996-08-23 | 2005-10-16 | Endo Pharmaceuticals Inc | Composicion que contiene un anticonvulsionante para tratar el dolor neuropatico. |
| US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
| US5958919A (en) | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
| US5919826A (en) | 1996-10-24 | 1999-07-06 | Algos Pharmaceutical Corporation | Method of alleviating pain |
| ATE229004T1 (de) | 1997-03-31 | 2002-12-15 | Korea Res Inst Chem Tech | Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung |
| US6057373A (en) | 1997-05-22 | 2000-05-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
| US5866585A (en) | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
| IL133235A (en) | 1997-06-30 | 2004-02-19 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane nmda receptor antagonists and pharmaceutical compositions comprising them |
| US6071966A (en) | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
| US5783700A (en) | 1997-07-03 | 1998-07-21 | Nichols; Alfred C. | Quinolic acid derivatives |
| BR9814867A (pt) | 1997-10-24 | 2000-10-03 | Warner Lambert Co | Método para tratar discinesias relacionadas a doenças ou induzidas por drogas |
| US6177434B1 (en) | 1997-12-16 | 2001-01-23 | The United States Of America As Represented By The Secretary Of The Navy | Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| US6242456B1 (en) | 1998-03-09 | 2001-06-05 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
| US6054451A (en) | 1998-04-21 | 2000-04-25 | Algos Pharmaceutical Corporation | Analgesic composition and method for alleviating pain |
| PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
| DE69931316D1 (de) * | 1998-08-18 | 2006-06-22 | Hoffmann La Roche | Verwendung von Aryl-Cyclohexylamine Derivaten zur Herstellung von NMDA-Rezeptorblockern |
| US6200990B1 (en) | 1998-12-21 | 2001-03-13 | Alcon Laboratories, Inc. | Neuroprotective agents having antioxidant and NMDA antagonist activity |
| DE60005517T2 (de) * | 1999-06-29 | 2004-07-01 | Neurosearch A/S | Kaliumkanal-blockierende mittel |
| EP1070708B1 (en) | 1999-07-21 | 2004-01-14 | F. Hoffmann-La Roche Ag | Triazole derivatives |
| GB9917822D0 (en) | 1999-07-29 | 1999-09-29 | Imperial College | Nmda antagonist |
| US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| US7375136B2 (en) * | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
-
2002
- 2002-03-08 US US10/469,824 patent/US7375136B2/en not_active Expired - Fee Related
- 2002-03-08 JP JP2002571458A patent/JP2005506292A/ja active Pending
- 2002-03-08 WO PCT/US2002/007033 patent/WO2002072542A2/en not_active Ceased
- 2002-03-08 EP EP02719157A patent/EP1436258A4/en not_active Withdrawn
- 2002-03-08 AU AU2002250256A patent/AU2002250256B2/en not_active Ceased
- 2002-03-08 CA CA002440284A patent/CA2440284A1/en not_active Abandoned
-
2008
- 2008-05-08 US US12/151,633 patent/US20090023791A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506292A5 (cg-RX-API-DMAC7.html) | ||
| US7375136B2 (en) | pH-dependent NMDA receptor antagonists | |
| AU2002250256A1 (en) | pH-dependent NMDA receptor antagonists | |
| TWI655187B (zh) | 作爲鈉通道調節劑之吡啶酮醯胺 | |
| JP2006501202A (ja) | Ｍｃｈ調節作用を有するジアリール置換環状尿素誘導体 | |
| WO1999020620A1 (en) | Isoquinoline derivative and drug | |
| JP2013532178A (ja) | 抗アンドロゲン特性を有する新規なアリールアミド誘導体 | |
| KR20010024220A (ko) | 신규한 ｎｐｙ 길항제 | |
| US12391664B2 (en) | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor | |
| RU2655919C2 (ru) | Производные аминоциклобутана, способ их получения и их применение в качестве лекарственных средств | |
| JP2006515618A (ja) | 置換アルキルアミドピペリジン類 | |
| EP1753725B1 (fr) | Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique | |
| US7576129B2 (en) | Carboxylic acid compounds | |
| JPH0549673B2 (cg-RX-API-DMAC7.html) | ||
| EP0426804B1 (en) | 2-(2-hydroxy-3-phenoxypropylamino)-ethoxybenzene derivatives | |
| WO2022129047A2 (en) | Novel modulators of the nmda receptor | |
| AU2008201372A1 (en) | Ph-Dependent NMDA receptor antagonists | |
| JP2003529532A (ja) | ４−３−置換−アミノ−シクロブト−３−エン−１，２−ジオン及び平滑筋収縮に影響を及ぼすための使用 | |
| JPH11335275A (ja) | ニトロン誘導体経皮剤 | |
| JPH0363253A (ja) | 神経循環活性を有する２―アミノ―１，２，３，４―テトラヒドロナフタレン誘導体、その製造法及びそれらを含む製薬組成物 | |
| US20220133892A1 (en) | Chimeric Compounds and Methods of Managing Neurological Disorders or Conditions | |
| PT93725A (pt) | Processo para a preparacao de derivados de benzopirano anti-hipertensivos | |
| WO2023133457A1 (en) | Novel kalirin inhibitors for regulation of synaptic plasticity and neuropathic pain treatment | |
| WO2024255859A1 (zh) | 作为at2r拮抗剂的杂环化合物及其用途 | |
| HK1212968B (en) | Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs |